Roxana Siles, MD
Allergy & Immunology · Cleveland, OHNPI 1255518767
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,334 of the $5,580 with a category attached, or 77.7%. 10 manufacturers reported payments, led by AstraZeneca at 53.2% of the total. Reporting peaked in 2022 at $2,848 and has fallen 95.5% since, to $129 in 2025.
Across 21 payments — averaging $265.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$279
- CSL Behring$125
- Phadia US Inc.$117
- Teva Pharmaceuticals USA, Inc.$114
- plus $209 from 4 others
What the payments were for
- Consulting fees$4,33478%
- Food & beverage$1,20422%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $2,967 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,770 |
| Sanofi | 3 | $279 |
| CSL Behring | 1 | $125 |
| Phadia US Inc. | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $114 |
| GSK | 1 | $95 |
| Pfizer | 3 | $54 |
| Chiesi USA, Inc. | 1 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,580 in reported general payments places this provider in the 65th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 49 | $234,913 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $169,198 |
| XembifyImmune Globulin,gamma(Igg)klhw | 33 | $128,067 |
| NucalaMepolizumab | 24 | $84,118 |
| Advair HfaFluticasone Propion/Salmeterol | 93 | $62,475 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $40,626 |
| DuleraMometasone/Formoterol | 55 | $25,757 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $23,383 |
| Arnuity ElliptaFluticasone Furoate | 63 | $18,420 |
| Epinephrine | 52 | $11,846 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $9,451 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 76 | $9,045 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,271 |
| Azelastine Hcl | 205 | $5,746 |
| AirsupraAlbuterol Sulfate/Budesonide | 11 | $4,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $95 | $166,548200 claims |
| AstraZenecaSymbicort, Airsupra | $2,967 | $12,07731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Cleveland
- David LangCleveland$251K
- James FernandezCleveland$179K
- Joao Pedro Matias LopesCleveland$60K
- Mark AronicaCleveland$15K
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
- Adam UpdegraffToledo$379K
- Syed RehmanToledo$374K
- Gordon MyersCincinnati$346K
- Nancy Wasserbauer KingstonRocky River$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.